Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 46 to 60 of 60 results for diabetic foot

  1. Additional research could help address uncertainties in the evidence, although the case for cost savings remains unlikely. Although the committee acknowledged that the Game et al. (2018) RCT was well conducted, it felt that additional research could help resolve some uncertainties around the cost and clinical case for 3C Patch. Specifically, research identifying the most appropriate stopping rule, and the associated clinical outcomes of implementing the rule, would help address key uncertainties within the cost case. Additional collection of resource use data on unhealed hard-to-heal ulcers could also reduce uncertainty in the cost case. Further to this, evidence could be collected on an UrgoStart-experienced population, as this would be reflective of current NHS care. Clinical experts thought a trial on this population would be feasible. The committee concluded that although further research could be done, on balance it was unlikely to result in a cost-saving case for 3C Patch based on the decision problem evaluated in this guidance

    guidance details Comes from guidance 3C Patch for treating diabetic foot ulcers Number MTG66 Date issued March 2022

    Research recommendation
    Published
    8 April 2022

  2. Diabetes: annual foot examination (children) (IND54)

    This indicator covers the proportion of children and young people with diabetes who have a record of a foot examination in the previous 12 months. It measures outcomes that reflect the quality of care or processes linked by evidence to improved outcomes. This indicator was previously published as CCG73

    Network / system level indicators
    Last updated
    6 November 2020

  3. Oxyzyme and Iodozyme 2-layer hydrogel wound dressings with iodine for treating chronic wounds (MIB11)

    NICE has developed a Medtech Innovation Briefing (MIB) on Oxyzyme and Iodozyme 2-layer hydrogel wound dressings with iodine for treating chronic wounds

    Medtech innovation briefing
    Published
    19 November 2014

  4. Leg ulcer infection: antimicrobial prescribing (NG152)

    This guideline sets out an antimicrobial prescribing strategy for adults with leg ulcer infection. It aims to optimise antibiotic use and reduce antibiotic resistance.

    Antimicrobial prescribing guideline
    Published
    11 February 2020
    View recommendations

    Sections for NG152

  5. Managing long-term conditions in the community

    NICE's impact on managing long-term conditions in children in the community

  6. Diabetic foot problems: Inpatient management of diabetic foot problems (CG119)

    This guidance has been updated and replaced by NICE guideline NG19.

    Clinical guideline
    Published
    23 March 2011

  7. What is the most clinically and cost-effective tool for diagnosing peripheral arterial disease in people with diabetes?

    higher risk of cardiovascular events and foot problems such as diabetic neuropathy (nerve damage or degeneration),...

    Research recommendation
    Published
    22 January 2021

  8. Synthetic cartilage implant insertion for first metatarsophalangeal joint osteoarthritis (hallux rigidus) (IPG727)

    Evidence-based recommendations on synthetic cartilage implant insertion for first metatarsophalangeal joint osteoarthritis (hallux rigidus). This involves replacing damaged cartilage with an artificial (synthetic) implant.

    Interventional procedures guidance
    Published
    1 June 2022
    View recommendations

    Sections for IPG727

  9. Further research is needed on the benefits and consequences of detecting preclinical diabetic peripheral neuropathy.

    research is needed on the benefits and consequences of detecting preclinical diabetic peripheral neuropathy. Any explanatory notes(if...

    Research recommendation
    Published
    3 January 2019

  10. Research recommendations

    contact casting, hyperbaric oxygen therapy and surgical debridement for diabetic foot problems. CG119/1

  11. 3C Patch System for treating diabetic foot ulcers (MIB230)

    This advice has been updated and replaced by NICE medical technologies guidance 66.

    Medtech innovation briefing
    Published
    27 October 2020

  12. NICE and health inequalities

    Our health inequalities guidance supports strategies that improve population health as a whole, while offering particular benefit to the most disadvantaged

  13. Finerenone for treating chronic kidney disease in type 2 diabetes (TA877)

    Evidence-based recommendations on finerenone (Kerendia) for stage 3 and 4 chronic kidney disease (with albuminuria) associated with type 2 diabetes in adults.

    Technology appraisal guidance
    Published
    23 March 2023
    View recommendations

    Sections for TA877

  14. The Versajet II hydrosurgery system for surgical debridement of acute and chronic wounds and burns (MIB1)

    NICE has developed a Medtech Innovation Briefing (MIB) on the Versajet II hydrosurgery system

    Medtech innovation briefing
    Published
    4 February 2014

  15. Type 2 diabetes foot problems: Prevention and management of foot problems (CG10)

    This guidance has been updated and replaced by NICE guideline NG19.

    Clinical guideline
    Published
    28 January 2004